June 16, 2021
Eisai said on June 15 that it has entered into an agreement to divest its rights to the anti-epileptic agent Zonegran (zonisamide) in Europe, the Middle East, Russia, and Australia to UK drug maker Advanz Pharma for an undisclosed sum...read more